11 Dec 2023
ISB 1442

Poster: Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Kazandjian D. et al.

American Society of Hematology Annual Meeting


 

10 Dec 2023
ISB 1342

Poster: Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Kapoor P. et al.

American Society of Hematology Annual Meeting


 

10 Dec 2023
ISB 2001

Poster: A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma (RRMM)

Sia H. et al.

American Society of Hematology Annual Meeting


 

5th Nov 2023
GRC 54276

Clinical Abstract: Phase 1 First In Human Study Evaluating The Safety, Tolerability, Pharmacokinetics And Efficacy Of Grc54276, A Novel HPK1 Thronine-Kinase Inhibitor, In Advanced Solid Tumours And Lymphomas.

Doddihal H. et. al.

European Hematology Association


 

22 May 2023
ISB 1342

Pre-clinical Characterization of ISB 1342, a CD38xCD3 T-cell Engager for Relapsed/Refractory Multiple Myeloma

Perro M. et al.

Blood


 

17 Apr 2023
ISB 2001

Overcoming Mechanisms of Escape from Treatments for Multiple Myeloma by ISB 2001, a first-in-Class Trispecific BCMA and CD38 targeted T Cell Engager

Perro M. et al.

American Association for Cancer Research Annual Meeting